Exenatide — Indexed Studies

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.

Campbell C, McMillan HJ, Mah JK et al.

A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers.

Attie KM, Borgstein NG, Yang Y et al.

ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus).

Cadena SM, Bogdanovich S, Khurana TS et al.

ACE-031, a Soluble Activin Type IIB Receptor, Increases Muscle Mass and Strength in the Common Marmoset (Callithrix jacchus).

Cadena SM, Bogdanovich S, Khurana TS et al.

Gel Electrophoretic Detection of Black Market ACE-031.

Reichel C, Filip T, Gmeiner G et al.

The relationship between myodural bridge, atrophy and hyperplasia of the suboccipital musculature, and cerebrospinal fluid dynamics.

Yang H, Wei XS, Gong J et al.

The relationship between myodural bridges, hyperplasia of the suboccipital musculature, and intracranial pressure.

Li C, Yue C, Liu ZC et al.

Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs.

Thevis M, Schänzer W

[Anti-myostatin antibody therapy for myopathies].

Sunada Y

[Myostatin blockade therapy for muscular atrophy].

Sunada Y

Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type.

Cadena SM, Tomkinson KN, Monnell TE et al.

Gateways to clinical trials.

Tomillero A, Moral MA